Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Gerngross
Ingbert Gerngross, Reutlingen DE
| Patent application number | Description | Published |
|---|---|---|
| 20090027861 | Enclosure including an electrical module - A module includes an electrical component having an inner enclosure which surrounds the electrical component and which has first electrical contact means at least on one outer side; having an outer enclosure in the interior of which the inner enclosure is situated, the outer enclosure having second electrical contact means, the second electrical contact means extending from the interior to at least one outer side of the outer enclosure. The first and second contact means are interconnected. | 01-29-2009 |
Tillman Gerngross, Hanover, NH US
| Patent application number | Description | Published |
|---|---|---|
| 20090136525 | Immunoglobulins Comprising Predominantly a Glcnacman3Glcnac2 Glycoform - Compositions and methods for producing compositions comprising immunoglobulins or immunoglobulin fragments having an N-linked glycosylation pattern consisting predominantly of the GlCNAcMan | 05-28-2009 |
| 20110135707 | POLYHYDROXYALKANOATES FOR IN VIVO APPLICATIONS - Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial system (RES), are described. Methods for depyrogenating PHA polymers prepared by bacterial fermentation processes are also provided, wherein pyrogens are removed from the polymers without adversely impacting the polymers' inherent chemical structures and physical properties. PHAs with advantageous processing characteristics, including low melting points and/or solubility in non-toxic solvents, are also described. PHAs are provided which are suitable for use in in vivo applications such as in tissue coatings, stents, sutures, tubing, bone and other prostheses, bone or tissue cements, tissue regeneration devices, wound dressings, drug delivery, and for diagnostic and prophylactic uses. Properties which are selected for include degradability, elasticity, inclusion of functional groups or derivatized groups, which can in turn be used to attach targeting agents, and bioadhesion. | 06-09-2011 |
Tillman Ulf Gerngross, Hanover, NH US
| Patent application number | Description | Published |
|---|---|---|
| 20110053214 | PRODUCTION OF GALACTOSYLATED GLYCOPROTEINS IN LOWER EUKARYOTES - The present invention provides a novel lower eukaryotic host cell producing human-like glycoproteins characterized as having a terminal β-galactose residue and essentially lacking fucose and sialic acid residues. The present invention also provides a method for catalyzing the transfer of a galactose residue from UDP-galactose onto an acceptor substrate in a recombinant lower eukaryotic host cell, which can be used as a therapeutic glycoprotein. | 03-03-2011 |